Christoph Nowak
Hoofd Techniek/Wetenschap/O&O bij DIAMYD MEDICAL AB
Vermogen: 581 $ op 30-04-2024
Actieve functies van Christoph Nowak
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
DIAMYD MEDICAL AB | Hoofd Techniek/Wetenschap/O&O | - | - |
ONCOZENGE AB | Directeur/Bestuurslid | 09-09-2023 | - |
Independent Dir/Board Member | 09-09-2023 | - | |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Hoofd Techniek/Wetenschap/O&O | - | - |
Loopbaan van Christoph Nowak
Eerdere bekende functies van Christoph Nowak
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Karolinska Institutet | Corporate Officer/Principal | - | - |
Opleiding van Christoph Nowak
University of Uppsala | Doctorate Degree |
University of Oxford | Doctorate Degree |
Technische Universität Braunschweig | Graduate Degree |
Statistieken
Internationaal
Zweden | 6 |
Verenigd Koninkrijk | 2 |
Duitsland | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 2 |
Graduate Degree | 1 |
Sectoraal
Consumer Services | 5 |
Health Technology | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
DIAMYD MEDICAL AB | Health Technology |
ONCOZENGE AB | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Health Technology |
- Beurs
- Insiders
- Christoph Nowak
- Ervaring